A single dose that could keep the sickest from the hospital
In the spring of 2021, as vaccines raced against a still-mutating virus, two pharmaceutical companies offered a different kind of answer to COVID-19's toll: not prevention, but rescue. The FDA's emergency authorization of sotrovimab — a monoclonal antibody developed by GlaxoSmithKline and Vir Biotechnology — marked a quiet but consequential expansion of medicine's capacity to intervene after infection had already taken hold. For the elderly, the immunocompromised, and the unreached, it represented something vaccines alone could not yet promise: a single dose standing between a diagnosis and a hospital bed.
- An 85% reduction in hospitalizations and death gave sotrovimab immediate credibility in a landscape crowded with therapeutic uncertainty.
- The antibody's apparent effectiveness against all known variants — including the emerging India strain — raised the stakes, suggesting it could hold its ground even as the virus continued to evolve.
- Emergency authorization created a bridge for high-risk patients who could not wait for full approval, but the regulatory finish line remained months away.
- Clinical trial data expected by day 29 of treatment would determine whether a formal Biologics License Application could be filed in the second half of 2021.
- Doctors gained a post-infection tool to complement vaccines, widening the protective net for populations that immunization alone had not yet fully covered.
On a May morning in 2021, GlaxoSmithKline and Vir Biotechnology announced that the FDA had granted emergency use authorization for sotrovimab, a monoclonal antibody treatment for adults and children with mild-to-moderate COVID-19 who faced elevated risk of severe illness or death. The authorization was grounded in interim data showing an 85% reduction in hospitalizations and deaths — a figure that carried weight at a moment when the pandemic's human cost remained staggering.
What distinguished sotrovimab from other therapeutic approaches was its apparent resilience against variants. According to Vir's chief executive George Scangos, the antibody appeared effective against every known strain circulating at the time, including a newly identified variant emerging from India — a property that suggested it might hold up even as the virus continued to mutate.
The timing mattered. Vaccines were rolling out across the United States, but not universally or quickly enough, and some patients could not receive them at all. Sotrovimab offered something different: a single-dose intervention for people who had already contracted the virus, aimed at keeping them out of the hospital rather than preventing infection in the first place.
The emergency authorization was not the end of the road. Ongoing clinical trials were expected to yield more complete data by day 29 of treatment, which the companies planned to incorporate into a full Biologics License Application to be filed with the FDA in the second half of 2021. Emergency authorization was a bridge — a way to reach patients while the longer machinery of formal drug approval continued its work. For those most vulnerable to COVID-19's worst outcomes, that bridge was the point.
On a May morning in 2021, two pharmaceutical companies announced they had cleared a significant regulatory hurdle: the FDA had granted emergency authorization for a new weapon against COVID-19, a monoclonal antibody treatment called sotrovimab, developed jointly by GlaxoSmithKline and Vir Biotechnology. The drug was approved for use in adults and children with mild-to-moderate COVID-19 who faced elevated risk of severe illness, hospitalization, or death.
The authorization rested on interim laboratory data that showed the treatment reduced hospitalizations and deaths from all causes by 85 percent. More than that, the antibody appeared to work against every known variant of concern circulating at the time, including a newly identified strain emerging from India. For Vir's chief executive, George Scangos, the finding suggested the treatment could remain effective even as the virus continued to mutate—a property that had eluded many other therapeutic approaches.
What made this moment significant was its timing and scope. Vaccines were already rolling out across the United States, but they were not reaching everyone fast enough, and some people could not receive them at all. A treatment that could be given as a single dose to high-risk patients offered a different kind of protection: not prevention, but intervention. If someone got sick, sotrovimab could potentially keep them out of the hospital.
The companies were not finished with their work. Clinical trials were still underway, and they expected to have more complete safety and efficacy data by day 29 of treatment—results they said would come sometime in the first half of 2021. That data would feed into a formal Biologics License Application, the full regulatory submission they planned to file with the FDA in the second half of the year. Emergency authorization was a bridge; a standard approval would be the destination.
The authorization expanded the toolkit available to doctors treating COVID-19 patients. Vaccines prevented infection in most people. Monoclonal antibodies like sotrovimab offered a different strategy: they could be administered after someone had already contracted the virus, targeting the infection directly. For patients who were immunocompromised, elderly, or had other conditions that put them at serious risk, having a single-dose treatment available represented a meaningful addition to the arsenal against a disease that had already killed hundreds of thousands of Americans.
The path forward was clear, if uncertain. The companies would continue gathering data. Regulators would continue reviewing it. And somewhere in the gap between emergency authorization and full approval, sotrovimab would begin reaching patients who needed it—a holding action while the larger machinery of drug development ground forward.
Citações Notáveis
The antibody treatment showed an 85% reduction in all-cause hospitalizations or death and is effective against all known variants of concern, including the emerging variant from India.— George Scangos, Vir Biotechnology CEO
A Conversa do Hearth Outra perspectiva sobre a história
Why does a single-dose treatment matter so much when we already have vaccines?
Because not everyone can get vaccinated, and not everyone who gets vaccinated is protected equally. An immunocompromised person, an elderly patient with multiple conditions—they need options. A treatment you can give after someone's already sick fills a gap vaccines can't.
The 85 percent reduction in hospitalizations—how confident should we be in that number?
It's interim data from a lab analysis, not the full clinical trial yet. That's why it's emergency authorization, not full approval. The number is real, but it's preliminary. They're still running the trials.
What's the significance of it working against all known variants, including the India variant?
Most treatments lose effectiveness as the virus mutates. This one didn't—at least not in the lab. That's unusual and valuable. It suggests the antibody targets something fundamental about the virus that doesn't change easily.
So this is a bridge to something bigger?
Exactly. Emergency authorization gets it to patients now. The full Biologics License Application later in the year is the real approval—the one that comes with complete safety data and longer-term follow-up.
Who benefits most from this?
High-risk patients who get sick. The elderly, the immunocompromised, people with serious underlying conditions. Not everyone—just those most likely to end up hospitalized.